fda warning letters compounding semaglutide september 2025 Last month, the issued 25 to telehealth companies over what it called false or misleading claims about compounded GLP-1 medications Ivím Health Raises Alarm as

Their main ability is to donate electrons to the oxidized molecules, being considered as powerful antioxidants (Castelli et al., 2018)

Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, and Creutzfeldt W

Semaglutide is FDA-approved for weight loss, type 2 diabetes, and other conditions

The drug is being developed by Eli Lilly, the same company behind Mounjaro, but its still several years away from potentially reaching the weight management market

Impact on supply planning Multi-peptide protocols increase complexity

Results are highly individual, and the best approach depends on your skins needs and response